NASDAQ: RNXTRenovorx Inc Stock
$1.11-0.22 (-16.54%)
Updated Oct 2, 2023
RNXT Price
$1.11
Fair Value Price
N/A
Market Cap
$11.82M
52 Week Low
$0.91
52 Week High
$5.75
P/E
-1.05x
P/B
9.95x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$9.88M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
4.32
Operating Cash Flow
-$10M
Beta
0.93
Next Earnings
Nov 13, 2023
Ex-Dividend
N/A
Next Dividend
N/A
RNXT Overview
Renovorx Incorporated is a clinical-stage biopharmaceutical company developing treatments for solid tumor. The company's lead product is RenovoGem, a drug and device combination that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Renovorx was founded in 2009 and is headquartered in Los Altos, CA.
Zen Score
–
Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how RNXT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
RNXT is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
RNXT is poor value based on its book value relative to its share price (9.95x), compared to the US Biotechnology industry average (5.05x)
P/B vs Industry Valuation
RNXT is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more RNXT due diligence checks available for Premium users.
Be the first to know about important RNXT news, forecast changes, insider trades & much more!
RNXT News
Valuation
RNXT price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.05x
Industry
14.19x
Market
12.38x
RNXT price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
9.95x
Industry
5.05x
RNXT is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
RNXT's financial health
Profit margin
Revenue
$0.0
Net Income
-$2.3M
Profit Margin
0%
RNXT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.3M
Liabilities
$5.1M
Debt to equity
4.32
RNXT's short-term assets ($6.31M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
RNXT's short-term assets ($6.31M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
RNXT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.8M
Investing
$0.0
Financing
$5.0M
RNXT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
RNXT vs Biotech Stocks
Renovorx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.